
Search for a benzodiazepine taper schedule and the results look reassuringly uniform. Reduce by a set percentage, wait a set number of weeks, repeat until zero.
Those schedules are easy to publish and difficult to live inside. The variables that decide whether a reduction is tolerable are specific to the patient, and a plan that ignores them tends to fail in predictable ways.
Because the same milligram cut is not the same event in two different nervous systems.
Benzodiazepines enhance the activity of gamma-aminobutyric acid (GABA), the brain’s main calming neurotransmitter, and long-term use leads the brain to reduce the number and sensitivity of its GABA receptors. That adaptation is physical dependence, and its depth depends on the drug, the dose, and the years behind it.
Physical dependence is not addiction. It is a pharmacological state produced by the medication, which is why the plan is engineered around pharmacology and patient history rather than around motivation.
A fixed percentage schedule assumes every patient starts from the same place. Almost none of them do.
It changes nearly everything about the shape of the taper.
Short-acting benzodiazepines such as alprazolam and lorazepam leave the bloodstream quickly, so patients often feel withdrawal between doses while still taking the medication as prescribed. That interdose pattern makes small reductions harder to tolerate and harder to interpret.
Longer-acting benzodiazepines hold a steadier blood level, which smooths the ground under each reduction. Potency differs as well, so a fraction of a milligram in one drug is not equivalent to a fraction of a milligram in another.
Z-drugs such as zolpidem and eszopiclone act on the same GABA-A receptors and follow the same tapering principles, with the same need for an individually sized plan.
It trades a short-acting drug for a long-acting one so that the taper can proceed on a stable baseline.
The crossover taper to diazepam is the approach described in the Ashton Manual, written by the late Professor C. Heather Ashton, and it is the preferred starting point in many cases. A steadier blood level tends to mean fewer interdose troughs, and diazepam’s availability in small increments makes fine reductions practical.
In Dr. Leeds’ clinical experience, patients who are able to taper with diazepam generally have a more comfortable taper and maintain better daily functioning while doing it.
The crossover itself is not a single maneuver applied identically to everyone. How much diazepam replaces how much of the original drug, and how gradually the substitution is made, are decisions made for the individual patient.
When diazepam is a poor fit for that particular patient.
Metabolism varies, and some patients process diazepam unusually slowly or unusually quickly, which makes a stable blood level harder to achieve. Others have had an allergy or an adverse reaction to diazepam or a related benzodiazepine.
In those cases the taper is done with the patient’s current benzodiazepine instead. For a patient taking alprazolam who cannot use diazepam, a crossover to clonazepam and a taper from there is the preferred alternative.
None of these are second-best outcomes. They are the correct plan for that patient, which is the whole point of building one.
Because the current dose says nothing about how deep the adaptation runs.
Two patients can both be taking one milligram a day. One has taken it for four months, the other for eleven years, and their nervous systems are not in the same condition.
Length of use, the highest dose ever reached, and whether the patient has ever been in tolerance withdrawal, where symptoms appear at an unchanged dose, all shape how a plan begins and how quickly it can move.
It usually means the next taper has to be slower, not faster.
Repeated abrupt or rapid withdrawals can cause kindling, in which each episode leaves the nervous system more reactive and the next withdrawal more severe. A patient arriving after two hospital detoxes and a cold turkey attempt is not starting fresh.
This history is often the single most important thing a new patient can report, and it is frequently the thing nobody has asked them about.
Because the relationship between dose and receptor occupancy is not a straight line.
At higher doses, receptors are close to saturated, so a reduction removes relatively little occupancy. Near the bottom of the range, the same size cut removes a much larger share, which is why the final stretch of a taper is usually the slowest.
Reductions that shrink as the dose falls are what is meant by hyperbolic tapering, and it is the principle behind the Maudsley Deprescribing Guidelines as well as the Ashton Manual. How small the steps need to become, and how often, is again individual.
Everything that determines whether the patient can absorb the next reduction.
Other medications matter, both for interactions and because a nervous system managing several changes at once has less capacity for any of them. Consistency of the medication source matters too, since switching between manufacturers mid-taper can shift absorption enough to destabilize a steady schedule.
Life circumstances count as clinical information. A patient in the middle of a move, a demanding stretch at work, or a family crisis is carrying a stress load that changes what a reduction will cost, and the schedule can wait.
Mark Leeds, D.O. is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and he serves on the medical advisory board of the Benzodiazepine Information Coalition. His practice provides medically supervised benzodiazepine and z-drug tapering by secure telemedicine throughout Florida.
Every plan starts with the specifics: which medication, how long, what the highest dose was, what previous attempts looked like, what else the patient takes, and what their life currently demands. Patients work directly with Dr. Leeds at weekly appointments, and the plan is revised against their actual response rather than defended as written.
A taper plan is not a template with a name typed at the top. It is an argument about one person’s pharmacology, history, and circumstances, and it should be able to explain itself.
A patient is entitled to know why their plan looks the way it does: why this medication, why this step size, why this pace. If the answer is that the schedule came from a chart, the plan was built for nobody in particular.
If you want a taper designed around your own history rather than a standard protocol, that work starts with a detailed conversation. For medically supervised benzodiazepine tapering built for one patient at a time, contact Dr. Leeds today through the contact page.

Dr. Leeds specializes in the Ashton Method, a well-established and evidence-based protocol for tapering off benzodiazepines. Developed by the renowned Dr. Heather Ashton, the Ashton Method provides a structured and safe approach to gradually reducing benzodiazepine dosages, minimizing withdrawal symptoms, and ultimately achieving freedom from these medications.
Contact Us for expert guidance on safely tapering off benzodiazepines and reclaiming your life.





